At a Glance
  • Status: Completed Consortium
  • Year Launched: 2006
  • Initiating Organization: European Commission Sixth Framework Programme (FP6)
  • Initiator Type: Government
  • Disease focus:
    Cancers
  • Location: Europe

Abstract

As death rates from cancer decline, scientists are encouraged by recent advances in prevention, early diagnosis, and therapy.  Efforts are being made towards the generation of “smart” anti-cancer drugs that will target specific molecules depending on the molecular phenotyping of the patient’s tumor.  TNF-related apoptosis-inducing ligand (TRAIL) is currently a promising anti-tumor agent with proven activity on several cell and animal cancer models. A unique feature of TRAIL is its specificity towards malignant cells, which is what this project is seeking to utilize in identifying components of colon tumors, which confer sensitivity or resistance to cell death induced by TRAIL. 

Mission

The ONCODEATH Project is concerned with a unique approach to cancer treatment: the analysis of defective apoptotic pathways in colon tumour cells in a oncogene dependent manner in order to exploit them for novel treatment protocols based on TRAIL as a ''monotherapy'' or in combination with novel pathway specific inhibitors, like PI3K, Rho and aurora kinase pathways. In combination therapies the two drugs can be used in low concentrations, thus minimizing side-effects. Moreover, drugs targeting signaling pathways allow or amplify the activity of TRAIL by targeting resistance mechanisms and pathways in particular tumours. This treatment has been already been successful in both in vitro and in vivo applications. The ultimate goal is to shift the therapeutic emphasis to tumour specific drugs, with a consequence for low hospitalization time, costs, and high efficiency.

Structure & Governance

European Commission Sixth Framework Programme (FP6)

Financing

European Commission Sixth Framework Programme (FP6)

Impact/Accomplishment

For a list of accomplishments, click here

Points of Contact

Laboratory of Signal Mediated Gene Expression
Institute of Biological Research and Biotechnology (I.B.R.B.)
National Hellenic Research Foundation (N.H.R.F.)
48 Vas. Constantinou Ave., 116 35 Athens, Greece
Tel: +302107273753, +302107273745
Fax: +302107273755
e-mail: apint@eie.gr
http://www.eie.gr/nhrf/institutes/ibrb/programmes/smgenexp-en.html

Sponsors & Partners

Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology

Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics

Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research

Breakthrough Breast Cancer Research Centre, Cancer Research UK, Institute of Cancer Research

Dept. of cell biology, University of Geneva

Instituto de Investigaciones Biomedicas, C/ Arturo Duperier 4, 28029 Madrid

Equipe de Morphogenese et Signalisation cellulaires, UMR 144 CNRS/Institut Curie

Molecular Biology Department, DTCA HYGEIA Hospital


Last Updated: 06/20/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.